Our science

The immune system can’t fight what it can’t see.

Most solid tumors remain functionally invisible to the immune system. It is a problem of recognition, not strength, and it is the problem LurexBio was designed to address.

Explore the platform
See the pipeline
Recognition gap

The immune system can’t fight what it can’t see.

Immune-cold tumors are characterized by few tumor-infiltrating lymphocytes, impaired antigen presentation, and weak immune signaling. Without sufficient cues, the immune system cannot identify them, and existing immunotherapies have no functional target to act on.

Explore the platform
Immune cells passing an unmarked tumor cell
Downstream

Most therapies work downstream of recognition.

Checkpoint inhibitors, cell therapies, and vaccines are designed to strengthen or redirect an immune response that already exists. In many solid tumors, the core limitation is upstream: the immune system cannot respond to what it cannot recognize.

Explore the platform
Immune cells beside a tumor they cannot recognize
Upstream

Recognition first. Amplification second.

Other immunotherapies make the immune system’s attack stronger, but that only helps if the tumor has already been spotted. LurexBio is designed to address that first step by placing a marker the immune system already recognizes directly on the tumor surface.

Explore the platform
A T cell recognizing a marker on the tumor surface
3 steps

Recognition, engineered in three steps.

Install the signal with NeoTag™. Deliver it cleanly with Atraxis™, with no genetic editing and no viral vectors. Govern the response with AegisCore™, coordinated by StratIQ™.

Explore the platform
The four LurexBio platform layers working together at the tumor surface

1. Install the signal

NeoTag™ is designed to place recognizable immune markers on the tumor surface.

2. Deliver it cleanly

Atraxis™ is designed to fuse the signal onto the membrane, with no genetic editing and no viral vectors.

3. Govern the response

AegisCore™ is designed to keep activity in the right place and time, while StratIQ™ coordinates the system.

Four platforms · one operating system

The result, by design.

How NeoTag™, Atraxis™, AegisCore™ and StratIQ™ work in sequence.

  1. 01NeoTag™ · Signal
  2. 02Atraxis™ · Delivery
  3. 03AegisCore™ · Control
  4. 04StratIQ™ · Decision
  5. 05The result

Signal layer · NeoTag™

Install the signal

NeoTag™ is designed to place a marker the immune system already recognizes directly on the tumor surface, without editing the tumor genome.

Delivery layer · Atraxis™

Deliver it cleanly

Atraxis™ lipid vesicles are designed to carry that signal to the tumor and fuse with its membrane, with no genetic editing and no viral vectors.

Control layer · AegisCore™

Govern the response

AegisCore™ is designed to sense its surroundings, allow delivery only when the right conditions are met, and keep activity contained to the tumor region.

Decision layer · StratIQ™

Coordinate the system

StratIQ™ is designed to read the tumor environment and link NeoTag™, Atraxis™ and AegisCore™ so each layer acts in step with the others.

Working in concert

A tumor the immune system can see

A once-invisible tumor cell the immune system can read as a threat: visible to existing T-cell and NK-cell pathways, and designed to be compatible with the immunotherapies patients already receive. Validation is the goal of our preclinical work.

Illustrations are conceptual.

Where the
need is greatest.

Immune-cold tumors are where today’s immunotherapies fall short, and where demand for new approaches keeps growing.

$441B

Projected global spending on cancer medicines in 2029, up from $252B in 2024.

Source: IQVIA Institute, Global Oncology Trends 2025

41%

Of all clinical trials are in oncology, with 2,162 new cancer trials started in 2024.

Source: IQVIA Institute, Global Oncology Trends 2025

~95%

Of metastatic colorectal cancers are microsatellite stable (MSS), a largely immune-cold setting.

Source: Clin Adv Hematol Oncol, 2022

226,380

New US colorectal and pancreatic cancer cases expected in 2026, the diseases behind our two initial focus areas.

Sources: American Cancer Society, 2026 · ACS Cancer Statistics 2026, via PanCAN

The response gap

Most patients still don’t benefit from checkpoint inhibitors

Estimated share of US patients with cancer, 2018. Each square is 1%.

  • 12.5%estimated to respond
  • 31.2%eligible, but not expected to respond
  • 56.4%not eligible

Source: Haslam & Prasad, JAMA Netw Open 2019

The survival gap

Survival lags far behind in our focus indications

Five-year relative survival, United States

Sources: ACS Cancer Statistics 2026, via PanCAN · American Cancer Society, colorectal survival rates

Initial focus

MSS colorectal cancer

Most metastatic colorectal cancers are microsatellite stable (MSS), a largely immune-cold setting where checkpoint monotherapy has shown limited benefit.

  • 55,230US colorectal cancer deaths expected in 2026
  • 0%objective response to PD-1 blockade in mismatch-repair-proficient colorectal cancer in a landmark study

Sources: American Cancer Society, 2026 · Le et al., N Engl J Med 2015

Initial focus

Pancreatic ductal adenocarcinoma

One of the most immune-cold and aggressive malignancies, with high unmet need and poor outcomes.

  • 52,740US deaths expected in 2026, the third-leading cause of cancer death
  • 17%of patients are diagnosed at a localized stage

Sources: ACS Cancer Statistics 2026, via PanCAN · Lustgarten Foundation, 2026

Future opportunities

Beyond our initial focus

Immune-cold subsets of other solid tumors may represent future opportunities, subject to supportive data.

  • Breast
  • Prostate
  • Ovarian
  • Gastrointestinal

Figures describe the overall disease and market landscape, drawn from the published sources linked above. They are not LurexBio results.

What is an immune-cold tumor?

A tumor that fails to provoke a meaningful immune response, often because the immune system lacks the cues needed to recognize it as a threat.

What does non-genetic, non-viral mean?

Our approach is designed to act at the tumor cell surface. It does not edit the tumor genome and does not rely on viral vectors for delivery.

How is this different from other immunotherapies?

Most immunotherapies amplify or redirect a response that already exists. LurexBio is designed to work upstream, at the recognition step those therapies depend on.

What stage is LurexBio at?

LurexBio is a preclinical-stage company. Platform descriptions reflect design intentions and scientific hypotheses, not demonstrated results.

Guided by world-class
scientific advisors.

Meet our team

Connect with us

    Join us in advancing a new approach.

    We welcome conversations with investors, potential partners, and talented individuals who share our vision.

    Invest with lurexbio